Blog

  • Luciana Berger – 2015 Parliamentary Question to the Department of Health

    Luciana Berger – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Luciana Berger on 2015-11-25.

    To ask the Secretary of State for Health, whether the additional £600 million funding for mental health announced in the Spending Review and Autumn Statement 2015 is funding previously not included in figures for total spending of the Department involved.

    Alistair Burt

    The additional £600 million for mental health over the next five years announced in the Spending Review and Autumn Statement is additional to current spending. The levels of funding in individual years and the specific mental health service improvements it will fund will be determined in the new year, once the Mental Health Taskforce has reported.

  • Jess Phillips – 2015 Parliamentary Question to the Department of Health

    Jess Phillips – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Jess Phillips on 2015-11-25.

    To ask the Secretary of State for Health, what estimate his Department has made of the number of (a) surgical operations, (b) diagnostic tests and (c) endoscopy procedures which could be used to treat NHS patients and are available from independent sector healthcare providers in winter 2015-16.

    Jane Ellison

    Decisions about whether to use independent sector capacity are made at local level according to local need, as part of the operational management of capacity and demand.

  • Jess Phillips – 2015 Parliamentary Question to the Department of Health

    Jess Phillips – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Jess Phillips on 2015-11-25.

    To ask the Secretary of State for Health, what plans NHS England has to use capacity in independent sector hospitals to reduce waiting lists in 2015-16.

    Jane Ellison

    Decisions about whether to use independent sector capacity are made at local level according to local need, as part of the operational management of capacity and demand.

  • Jess Phillips – 2015 Parliamentary Question to the Department of Health

    Jess Phillips – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Jess Phillips on 2015-11-25.

    To ask the Secretary of State for Health, with reference to page 13 of the NHS’ Five Year Forward View, what progress NHS England has made on the commitment to give patients choice over where and how they receive care; and how progress on that commitment will be assessed.

    Ben Gummer

    NHS England is working to secure a sustained improvement in awareness, offer, operation and take up of choice by 2020. This includes supporting the independent Maternity Services Review, which is due for publication early in the New Year, and taking forward any recommendations that relate to choice; improving the quality of End of Life Care and the choices people should have about where they receive their care and where they choose to die; strengthening choice in both physical and mental health elective services, to ensure that the NHS honours patients’ legal rights to choice of who provides their care; and securing choice in the design and implementation of new care models for the future NHS.

    NHS England has brought this work together with their programmes on personal health budgets and integrated personal commissioning, under a new Director and with additional resource, to accelerate the work in all of these areas in support of the Five Year Forward View commitment to deliver greater patient empowerment. Improvements will be assessed through a new national assessment framework for clinical commissioning groups.

  • David Amess – 2015 Parliamentary Question to the Department of Health

    David Amess – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by David Amess on 2015-11-25.

    To ask the Secretary of State for Health, what steps his Department is taking to ensure the medicines optimisation programme’s principle of ensuring that the right patient gets the right choice of medicine, at the right time, is applied to people with inflammatory arthritis.

    Jane Ellison

    Quality standards (QS) are important in setting out to patients, the public, commissioners and providers what a high quality service should look like in a particular area of care. Whilst providers and commissioners must have regard to the National Institute for Health and Care Excellence (NICE) QS in planning and delivering services, however they are not mandatory.

    The QS for rheumatoid arthritis states that services should be commissioned from and coordinated across all relevant agencies encompassing the rheumatoid arthritis care pathway. A person-centred approach to provision of services is fundamental to delivering high-quality care to adults with rheumatoid arthritis. NHS England continues to champion their use with providers and commissioners.

    NHS England is working with patients, the pharmaceutical industry, royal colleges and others to encourage a range of improvements aimed at ensuring that all patients, including those with inflammatory arthritis, get the support they need to get the most from their medicines. The development of the four principles to support medicines optimisation offers a step change to the way we think about medicine use in the NHS. The four guiding patient-centred principles: aim to understand the patient’s experience; evidence-based choice of medicines; make medicines optimisation part of routine practice; ensure medicines use is as safe as possible are applicable to all patients, conditions and disease states.

    The medicines optimisation best practice guidance, published in May 2014 is available at:

    www.rpharms.com/promoting-pharmacy-pdfs/helping-patients-make-the-most-of-their-medicines.pdf.

    “

  • David Amess – 2015 Parliamentary Question to the Department of Health

    David Amess – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by David Amess on 2015-11-25.

    To ask the Secretary of State for Health, what assessment he has made of the effectiveness of implementation of the NICE quality standards for rheumatoid arthritis.

    Jane Ellison

    Quality standards (QS) are important in setting out to patients, the public, commissioners and providers what a high quality service should look like in a particular area of care. Whilst providers and commissioners must have regard to the National Institute for Health and Care Excellence (NICE) QS in planning and delivering services, however they are not mandatory.

    The QS for rheumatoid arthritis states that services should be commissioned from and coordinated across all relevant agencies encompassing the rheumatoid arthritis care pathway. A person-centred approach to provision of services is fundamental to delivering high-quality care to adults with rheumatoid arthritis. NHS England continues to champion their use with providers and commissioners.

    NHS England is working with patients, the pharmaceutical industry, royal colleges and others to encourage a range of improvements aimed at ensuring that all patients, including those with inflammatory arthritis, get the support they need to get the most from their medicines. The development of the four principles to support medicines optimisation offers a step change to the way we think about medicine use in the NHS. The four guiding patient-centred principles: aim to understand the patient’s experience; evidence-based choice of medicines; make medicines optimisation part of routine practice; ensure medicines use is as safe as possible are applicable to all patients, conditions and disease states.

    The medicines optimisation best practice guidance, published in May 2014 is available at:

    www.rpharms.com/promoting-pharmacy-pdfs/helping-patients-make-the-most-of-their-medicines.pdf.

    “

  • Nigel Dodds – 2015 Parliamentary Question to the Department of Health

    Nigel Dodds – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Nigel Dodds on 2015-11-25.

    To ask the Secretary of State for Health, what recent discussions he has had with his counterparts in the devolved administrations on the reform of the junior doctors’ contract.

    Ben Gummer

    My Rt. hon. Friend the Secretary of State for Health is in regular dialogue with the devolved administrations. Health is a devolved matter and it is for each administration to decide whether to seek to reform junior doctors’ contracts. All four countries were party to the negotiations that the British Medical Association walked away from in October 2014.

  • Peter Kyle – 2015 Parliamentary Question to the Department of Health

    Peter Kyle – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Peter Kyle on 2015-11-25.

    To ask the Secretary of State for Health, whether the £1.5 billion for the Better Care Fund by 2019-20 announced in the Autumn Statement 2015 is in addition to existing NHS financial allocations for the next five years.

    Alistair Burt

    From 2017 the Government will make adult social care funding available to local government, to be included in an improved Better Care Fund, rising to £1.5 billion in 2019-20. This is in addition to the NHS’s mandated contribution to the Better Care Fund, which will continue in real terms over the Parliament.

  • David Amess – 2015 Parliamentary Question to the Department of Health

    David Amess – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by David Amess on 2015-11-25.

    To ask the Secretary of State for Health, what steps he is taking to encourage the provision of take-home naloxone for at risk prisoners by health and justice lead area teams; and if he will make a statement.

    Jane Ellison

    The substance misuse element of the harm reduction strategy will align with national clinical guidance with regard to how naloxone and other medicines in the care pathway are considered for use, although specific medicines are unlikely to be named in the strategy.

    The commissioning of substance misuse treatment for prisoners is the responsibility of health and justice commissioning teams in ten of NHS England’s area teams, supported by a central health and justice team. The Government expects commissioners and providers of substance misuse services in prisons and in the community to work together closely in respect to prisoners being released from custody to ensure seamless transfers of care.

    Public Health England, the Department and the Medicines and Healthcare products Regulatory Agency have jointly published a factsheet[1] to explain October’s regulatory change with regard to naloxone and how the wider availability of naloxone affects relevant services. NHS England Area Teams will encourage providers to take account of this guidance.

    [1] https://www.gov.uk/government/publications/widening-the-availability-of-naloxone/widening-the-availability-of-naloxone

    “

  • Rachel Reeves – 2015 Parliamentary Question to the Department of Health

    Rachel Reeves – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Rachel Reeves on 2015-11-25.

    To ask the Secretary of State for Health, what the funding arrangements are in (a) England and (b) West Yorkshire hospitals for the use of Docetaxel chemotherapy medication.

    George Freeman

    The National Institute for Health and Care Excellence (NICE) is the independent body, which makes decisions on the clinical and cost effectiveness of products based on thorough assessment of the best available evidence. NICE has recommended docetaxel for the treatment of hormone-refractory metastatic prostate cancer (where the disease becomes unresponsive to hormone treatment). Commissioners are legally required to fund drugs and treatments recommended in NICE technology appraisal guidance.

    In the absence of guidance from NICE, it is for commissioners in England to make funding decisions on drugs and treatments based on the available evidence.